Properties (57)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
biologic drug
|
| gptkbp:activeDuring |
pegloticase
|
| gptkbp:approves |
gptkb:FDA
|
| gptkbp:availability |
prescription only
|
| gptkbp:clinicalTrials |
Phase 3
PEARL study PROTECT study improvement in gout symptoms reduction in serum uric acid CRYSTAL_study refractory_chronic_gout |
| gptkbp:contraindication |
fatigue
headache nausea vomiting anaphylaxis G6PD deficiency |
| gptkbp:dosageForm |
solution
|
| gptkbp:drugInterdiction |
half-life of 7-10 days
azathioprine mercaptopurine other urate-lowering therapies uric acid lowering agent |
| gptkbp:formulation |
sterile solution
|
| gptkbp:hasPopulation |
adults
|
| gptkbp:healthcare |
dietary recommendations
follow-up appointments renal function infusion reactions recognizing side effects importance of adherence hydration importance uric acid levels |
| https://www.w3.org/2000/01/rdf-schema#label |
Krystexxa
|
| gptkbp:impact |
every 2 weeks
|
| gptkbp:issuedBy |
intravenous infusion
|
| gptkbp:lastProduced |
2010
|
| gptkbp:mandates |
chronic_refractory_gout
|
| gptkbp:manufacturer |
gptkb:Horizon_Therapeutics
|
| gptkbp:marketedAs |
gptkb:Canada
gptkb:European_Union gptkb:United_States |
| gptkbp:offers |
$6,000 per treatment
|
| gptkbp:packaging |
vial
|
| gptkbp:patentExpiration |
2027
|
| gptkbp:provides |
ACR_guidelines
|
| gptkbp:regulatoryCompliance |
approved for use
|
| gptkbp:researchFocus |
long-term efficacy
safety in special populations comparative effectiveness |
| gptkbp:route |
IV
|
| gptkbp:safetyFeatures |
generally well tolerated
|
| gptkbp:sideEffect |
infusion reactions
gout flares |
| gptkbp:storage |
2 to 8 degrees Celsius
|
| gptkbp:triggerType |
uricase_enzyme
|
| gptkbp:usedFor |
chronic_gout
|